Table of Contents
ISRN Surgery
Volume 2012, Article ID 715743, 7 pages
http://dx.doi.org/10.5402/2012/715743
Review Article

Recent Advances in Biomarkers and Potential Targeted Therapies in Head and Neck Squamous Cell Carcinoma

Department of Otolaryngology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90089, USA

Received 22 August 2011; Accepted 26 September 2011

Academic Editor: D. E. Ziogas

Copyright © 2012 Eric J. Yavrouian and Uttam K. Sinha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. E. Vokes, R. R. Weichselbaum, S. M. Lippman et al., “Head and neck cancer,” New England Journal of Medicine, vol. 328, no. 3, pp. 184–194, 1993. View at Google Scholar
  2. R. Sankaranarayanan, E. Masuyer, R. Swaminathan, J. Ferlay, and S. Whelan, “Head and neck cancer: a global perspective on epidemiology and prognosis,” Anticancer Research, vol. 18, no. 6 B, pp. 4779–4786, 1998. View at Google Scholar · View at Scopus
  3. K. Shibuya, C. D. Mathers, C. Boschi-Pinto, A. D. Lopez, and C. J. L. Murray, “Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000,” BMC Cancer, vol. 2, no. 1, article 37, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. Forastiere, W. Koch, A. Trotti, and D. Sidransky, “Head and neck cancer,” New England Journal of Medicine, vol. 345, no. 26, pp. 1890–1900, 2001. View at Google Scholar · View at Scopus
  6. J. Califano, W. H. Westra, G. Meininger, R. Corio, W. M. Koch, and D. Sidransky, “Genetic progression and clonal relationship of recurrent premalignant head and neck lesions,” Clinical Cancer Research, vol. 6, no. 2, pp. 347–352, 2000. View at Google Scholar · View at Scopus
  7. D. M. Shin, J. S. Lee, and L. G. Choi, “Prognostic significance of p53 expression in head and neck Squamous cell carcinoma,” Proceedings of the American Society of Clinical Oncology, vol. 13, pp. 283–289, 1994. View at Google Scholar
  8. M. L. Poeta, J. Manola, M. A. Goldwasser et al., “TP53 mutations and survival in squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 357, no. 25, pp. 2552–2561, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. M. V. Gonzalez, M. P. Pello, C. Lopez-Larrea, C. Suarez, M. J. Menendez, and E. Coto, “Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 1, no. 9, pp. 1043–1049, 1995. View at Google Scholar
  10. J. A. Brennan, J. O. Boyle, W. M. Koch et al., “Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 332, no. 11, pp. 712–717, 1995. View at Publisher · View at Google Scholar · View at PubMed
  11. L. Mao, J. S. Lee, Y. H. Fan et al., “Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment,” Nature Medicine, vol. 2, no. 6, pp. 682–685, 1996. View at Publisher · View at Google Scholar
  12. D. J. Lee, F. Schönleben, V. E. Banuchi et al., “Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis,” Cancer Biology and Therapy, vol. 10, no. 7, pp. 689–693, 2010. View at Publisher · View at Google Scholar · View at PubMed
  13. http://www.clinicaltrials.gov/.
  14. M. P. Rosin, X. Cheng, C. Poh et al., “Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia,” Clinical Cancer Research, vol. 6, no. 2, pp. 357–362, 2000. View at Google Scholar
  15. J. J. Lee, W. K. Hong, W. N. Hittelman et al., “Predicting cancer development in oral leukoplakia: ten years of translational research,” Clinical Cancer Research, vol. 6, no. 5, pp. 1702–1710, 2000. View at Google Scholar
  16. O. Cuvillier, G. Pirianov, B. Kleuser et al., “Suppression of ceramide-mediated programmed cell death by sphingosine- 1-phosphate,” Nature, vol. 381, no. 6585, pp. 800–803, 1996. View at Publisher · View at Google Scholar · View at PubMed
  17. T. Kohama, A. Olivera, L. Edsall, M. M. Nagiec, R. Dickson, and S. Spiegel, “Molecular cloning and functional characterization of murine sphingosine kinase,” Journal of Biological Chemistry, vol. 273, no. 37, pp. 23722–23728, 1998. View at Publisher · View at Google Scholar
  18. S. M. Mandala, R. Thornton, Z. Tu et al., “Sphingoid base 1-phosphate phosphatase: a key regulator of sphingolipid metabolism and stress response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 1, pp. 150–155, 1998. View at Publisher · View at Google Scholar
  19. A. Olivera, T. Kohama, L. Edsall et al., “Sphingosine kinase expression increases intracellular sphingosine-1- phosphate and promotes cell growth and survival,” Journal of Cell Biology, vol. 147, no. 3, pp. 545–557, 1999. View at Publisher · View at Google Scholar
  20. S. Spiegel and S. Milstien, “Functions of the multifaceted family of sphingosine kinases and some close relatives,” Journal of Biological Chemistry, vol. 282, no. 4, pp. 2125–2129, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. U. K. Sinha, V. J. Schorn, C. Hochstim, S. B. Chinn, S. Zhu, and R. Masood, “Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition,” Head and Neck, vol. 33, no. 2, pp. 178–188, 2011. View at Publisher · View at Google Scholar · View at PubMed
  22. S. Kalyankrishna and J. R. Grandis, “Epidermal growth factor receptor biology in head and neck cancer,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2666–2672, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. Y. Yarden, “The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities,” European Journal of Cancer, vol. 37, supplement 4, pp. S3–S8, 2001. View at Google Scholar
  24. C. Kari, T. O. Chan, M. Rocha de Quadros, and U. Rodeck, “Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage,” Cancer Research, vol. 63, no. 1, pp. 1–5, 2003. View at Google Scholar
  25. X. H. Peng, P. Karna, Z. Cao, B. H. Jiang, M. Zhou, and L. Yang, “Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression,” Journal of Biological Chemistry, vol. 281, no. 36, pp. 25903–25914, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. A. Psyrri, Z. Yu, P. M. Weinberger et al., “Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis,” Clinical Cancer Research, vol. 11, no. 16, pp. 5856–5862, 2005. View at Publisher · View at Google Scholar · View at PubMed
  27. K. K. Ang, B. A. Berkey, X. Tu et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” Cancer Research, vol. 62, no. 24, pp. 7350–7356, 2002. View at Google Scholar
  28. J. R. Grandis, M. F. Melhem, W. E. Gooding et al., “Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 824–832, 1998. View at Google Scholar
  29. H. Sunada, B. E. Magun, J. Mendelsohn, and C. L. MacLeod, “Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 11, pp. 3825–3829, 1986. View at Google Scholar
  30. M. L. Jaramillo, Z. Leon, S. Grothe, B. Paul-Roc, A. Abulrob, and M. O'Connor McCourt, “Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting,” Experimental Cell Research, vol. 312, no. 15, pp. 2778–2790, 2006. View at Publisher · View at Google Scholar · View at PubMed
  31. M. Prewett, P. Rockwell, C. Rose, and N. I. Goldstein, “Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin,” International Journal of Oncology, vol. 9, no. 2, pp. 217–224, 1996. View at Google Scholar
  32. J. Mendelsohn, “Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy,” Clinical Cancer Research, vol. 3, no. 12, pp. 2703–2707, 1997. View at Google Scholar
  33. R. C. Lilenbaum, B. Johnson, T. Lynch et al., “The evolving role of cetuximab in non-small cell lung cancer,” Clinical Cancer Research, vol. 12, no. 14, pp. 4432s–4435s, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. S. Kim, J. R. Grandis, A. Rinaldo, R. P. Takes, and A. Ferlito, “Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer,” Head and Neck, vol. 30, no. 5, pp. 667–674, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at PubMed
  37. E. E. W. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at PubMed
  38. R. H. Wheeler, D. Jones, P. Sharma et al., “Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca),” Journal of Clinical Oncology, vol. 23, article 5531, 2005. View at Google Scholar
  39. E. E. W. Cohen, M. A. Kane, M. A. List et al., “Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 11, no. 23, pp. 8418–8424, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. L. L. Siu, D. Soulieres, E. X. Chen et al., “Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2178–2183, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. P. U. Hegde, A. C. Brenski, D. D. Caldarelli et al., “Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer,” Archives of Otolaryngology, vol. 124, no. 1, pp. 80–85, 1998. View at Google Scholar
  43. J. Folkman, “What is the evidence that tumors are angiogenesis dependent?” Journal of the National Cancer Institute, vol. 82, no. 1, pp. 4–6, 1990. View at Google Scholar
  44. J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995. View at Google Scholar
  45. J. Folkman, “Clinical applications of research on angiogenesis,” New England Journal of Medicine, vol. 333, no. 26, pp. 1757–1763, 1995. View at Publisher · View at Google Scholar · View at PubMed
  46. J. Folkman and D. Hanahan, “Switch to the angiogenic phenotype during tumorigenesis,” Princess Takamatsu Symposia, vol. 22, pp. 339–347, 1991. View at Google Scholar
  47. N. W. Gale and G. D. Yancopoulos, “Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development,” Genes and Development, vol. 13, no. 9, pp. 1055–1066, 1999. View at Google Scholar
  48. P. A. Kyzas, I. W. Cunha, and J. P. A. Ioannidis, “Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis,” Clinical Cancer Research, vol. 11, no. 4, pp. 1434–1440, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. L. Strauss, D. Volland, M. Kunkel, and T. E. Reichert, “Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance,” Medical Science Monitor, vol. 11, no. 8, pp. BR280–BR292, 2005. View at Google Scholar
  50. B. D. Smith, G. L. Smith, D. Carter, C. T. Sasaki, and B. G. Haffty, “Prognostic significance of Vascular Endothelial Growth Factor protein levels in oral and oropharyngeal squamous cell carcinoma,” Journal of Clinical Oncology, vol. 18, no. 10, pp. 2046–2052, 2000. View at Google Scholar
  51. J. P. H. Machiels, S. Henry, S. Zanetta et al., “Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at PubMed
  52. C. Elser, L. L. Siu, E. Winquist et al., “Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3766–3773, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. M. G. Fury, A. Zahalsky, R. Wong et al., “A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers,” Investigational New Drugs, vol. 25, no. 2, pp. 165–172, 2007. View at Publisher · View at Google Scholar · View at PubMed
  54. T. Y. Seiwert, D. J. Haraf, E. E. W. Cohen et al., “Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1732–1741, 2008. View at Publisher · View at Google Scholar · View at PubMed
  55. E. E. Cohen, D. W. Davis, T. G. Karrison et al., “Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study,” The Lancet Oncology, vol. 10, no. 3, pp. 247–257, 2009. View at Publisher · View at Google Scholar
  56. D. Sano, D. R. Fooshee, M. Zhao et al., “Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model,” Head and Neck, vol. 33, no. 3, pp. 349–358, 2011. View at Publisher · View at Google Scholar · View at PubMed
  57. N. Holder and R. Klein, “Eph receptors and ephrins: effectors of morphogenesis,” Development, vol. 126, no. 10, pp. 2033–2044, 1999. View at Google Scholar
  58. E. B. Pasquale, “The Eph family of receptors,” Current Opinion in Cell Biology, vol. 9, no. 5, pp. 608–615, 1997. View at Publisher · View at Google Scholar
  59. S. S. Gerety, H. U. Wang, Z. F. Chen, and D. J. Anderson, “Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development,” Molecular Cell, vol. 4, no. 3, pp. 403–414, 1999. View at Publisher · View at Google Scholar
  60. E. J. Yavrouian, U. K. Sinha, D. H. Rice, M. T. Salam, P. S. Gill, and R. Masood, “The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma,” Archives of Otolaryngology, vol. 134, no. 9, pp. 985–991, 2008. View at Publisher · View at Google Scholar · View at PubMed
  61. R. Masood, S. Ram Kumar, U. K. Sinha et al., “EphB4 provides survival advantage to squamous cell carcinoma of the head and neck,” International Journal of Cancer, vol. 119, no. 6, pp. 1236–1248, 2006. View at Publisher · View at Google Scholar · View at PubMed
  62. U. K. Sinha, K. Mazhar, S. B. Chinn et al., “The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma,” Archives of Otolaryngology, vol. 132, no. 10, pp. 1053–1059, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. U. K. Sinha, A. Kundra, P. Scalia et al., “Expression of EphB4 in head and neck squamous cell carcinoma,” Ear, Nose and Throat Journal, vol. 82, no. 11, pp. 866–887, 2003. View at Google Scholar
  64. M. J. Lace, J. R. Anson, J. P. Klussmann et al., “Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers,” Journal of Virology, vol. 85, no. 4, pp. 1645–1654, 2011. View at Publisher · View at Google Scholar · View at PubMed
  65. M. L. Gillison, W. M. Koch, R. B. Capone et al., “Evidence for a causal association between human papillomavirus and a subset of head and neck cancers,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 709–720, 2000. View at Google Scholar
  66. A. R. Kreimer, G. M. Clifford, P. Boyle, and S. Franceschi, “Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 2, pp. 467–475, 2005. View at Publisher · View at Google Scholar · View at PubMed
  67. M. E. McLaughlin-Drubin and K. Münger, “Oncogenic activities of human papillomaviruses,” Virus Research, vol. 143, no. 2, pp. 195–208, 2009. View at Publisher · View at Google Scholar · View at PubMed
  68. T. D. Kessis, R. J. Slebos, W. G. Nelson et al., “Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 9, pp. 3988–3992, 1993. View at Google Scholar
  69. K. Huh, X. Zhou, H. Hayakawa et al., “Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor,” Journal of Virology, vol. 81, no. 18, pp. 9737–9747, 2007. View at Publisher · View at Google Scholar · View at PubMed
  70. A. M. De Roda Husman, J. M. M. Walboomers, A. J. C. Van den Brule, C. J. L. M. Meijer, and P. J. F. Snijders, “The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR,” Journal of General Virology, vol. 76, no. 4, pp. 1057–1062, 1995. View at Google Scholar
  71. M. L. Gillison, J. Harris, and W. Westra, “Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129,” Proceedings of the American Society of Clinical Oncology, vol. 27, no. 15S, article 6003, 2009. View at Google Scholar
  72. C. Fakhry, W. H. Westra, S. Li et al., “Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial,” Journal of the National Cancer Institute, vol. 100, no. 4, pp. 261–269, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. D. Lindquist, M. Romanitan, L. Hammarstedt et al., “Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7,” Molecular Oncology, vol. 1, no. 3, pp. 350–355, 2007. View at Publisher · View at Google Scholar · View at PubMed
  74. L. Licitra, F. Perrone, P. Bossi et al., “High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5630–5636, 2006. View at Publisher · View at Google Scholar · View at PubMed
  75. http://www.cdc.gov/.
  76. A. Wu, Q. Zeng, T. H. Kang et al., “Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer,” Gene Therapy, vol. 18, pp. 304–312, 2011. View at Publisher · View at Google Scholar · View at PubMed
  77. S. Sethi, M. S. Benninger, M. Lu, S. Havard, and M. J. Worsham, “Noninvasive molecular detection of head and neck squamous cell carcinoma: an exploratory analysis,” Diagnostic Molecular Pathology, vol. 18, no. 2, pp. 81–87, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. J. Califano, S. A. Ahrendt, G. Meininger, W. H. Westra, W. M. Koch, and D. Sidransky, “Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients,” Cancer Research, vol. 56, no. 24, pp. 5720–5722, 1996. View at Google Scholar
  79. A. Matta, R. Ralhan, L. V. Desouza, and K. W. M. Siu, “Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery,” Mass Spectrometry Reviews, vol. 29, no. 6, pp. 945–961, 2010. View at Publisher · View at Google Scholar · View at PubMed
  80. R. Radhakrishnan, M. Solomon, K. Satyamoorthy, L. E. Martin, and M. W. Lingen, “Tissue microarray—a high-throughput molecular analysis in head and neck cancer,” Journal of Oral Pathology and Medicine, vol. 37, no. 3, pp. 166–176, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. X. León, M. Quer, S. Diez, C. Orús, A. López-Pousa, and J. Burgués, “Second neoplasm in patients with head and neck cancer,” Head and Neck, vol. 21, no. 3, pp. 204–210, 1999. View at Publisher · View at Google Scholar
  82. D. P. Slaughter, H. W. Southwick, and W. Smejkal, “Field cancerization in oral stratified squamous epithelium. Clinical implications of multicentric origin,” Cancer, vol. 6, pp. 963–968, 1953. View at Google Scholar
  83. E. Rennemo, U. Zätterström, and M. Boysen, “Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases,” Laryngoscope, vol. 118, no. 8, pp. 1350–1356, 2008. View at Publisher · View at Google Scholar · View at PubMed